Skip to content

Discovery pipeline‚Äč

Working in close collaboration with our clinical and industry partners we have discovered biomarker signatures in several disease areas.

Indication
Clinical question
Technology
Tissue
#patients
Outcome and Status
Sezary Syndrome (CTCL)
Diagnosis of CTCL
CyTOF
PBMCs
60 + 33
0.98 AUC; patent filed (EP19219889)
Flow-cytometry antibody panel prototype
Endometriosis
Diagnosis of endometriosis
scRNA-seq
PBMCs
42 + 60
0.9 AUC; patent filed (EP21204845)
Clinical validation and assay development
scRNA-seq
Endometrium
35 + 30
0.9 AUC; patent filed (EP21204856)
Clinical validation and assay development
Covid19 / ARDS
Prediction of ARDS development in Covid19-patients
CyTOF
PBMCs
Clinical data
37 + 17
0.95 – 1 AUC
Roussel et al., Cell Reports Medicine 2021
Non-Small Cell Lung Cancer (NSCLC)
Prediction of immunotherapy response
scRNA-seq
PBMCs
27 + 40
0.9 – 1.0 AUC; patent filed (EP21204836)
Clinical validation and assay development
DLBCL (CAR-T Cells)
Prediction of therapy response and toxicity
scRNA-seq
Infusion cell product
23
0.8 AUC efficacy prediction
1 AUC toxicity prediction
Solid tumors
(tg T cells)
Prediction of therapy response
scRNA-seq
Infusion cell product
14
Correlation of r = 0.75 with measured response
Service project
Helping you speed up your therapy development and increase your success rate